Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 9/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4412639 | 0.90 | GPR119 (0.46) | GPR119HDAC4HDAC6HDAC1 | |
| SCHEMBL13598312 | 0.90 | GPR119 (0.60) | GPR119HPGDHDAC4HDAC6KDM4E | |
| SCHEMBL4418689 | 0.85 | GPR119 (0.62) | GPR119HPGDHDAC4HDAC6HDAC1 | |
| SCHEMBL4414185 | 0.83 | GPR119 (0.50) | GPR119HDAC4HDAC6HDAC1 | |
| SCHEMBL4420008 | 0.83 | GPR119 (0.61) | GPR119HDAC4HDAC6HDAC1 | |
| SCHEMBL4414096 | 0.82 | GPR119 (0.49) | GPR119HPGDHDAC4HDAC6HDAC1 | |
| SCHEMBL4416116 | 0.81 | GPR119 (0.62) | GPR119HDAC4HDAC6HDAC1 | |
| SCHEMBL13598310 | 0.81 | GPR119 (0.62) | GPR119HDAC4HDAC6HDAC1 | |
| SCHEMBL4414343 | 0.80 | GPR119 (0.47) | GPR119HDAC4HDAC6TSHRTP53 | |
| SCHEMBL4412793 | 0.80 | GPR119 (0.64) | GPR119HDAC4HDAC6HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325924-A1 | GPCR Agonists | PROSIDION LIMITED (GB) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325924-A1 | GPCR Agonists | GPR119, GCGR, GPR27 | GPR119 1/4885HPGD 1902/4885HDAC4 2550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.